User:Medisinmannen/BCtect

BCtect® is a in-vitro diagnostic test for the quantitative measurement of gene expression in the blood of patients with suspected breast cancer that is sold under the trade name BCtect (Diagenic ASA).

The intended use for BCtect® is to aid in the diagnosis of breast cancer in adult women. It is intended that the BCtect® test is used together with other clinical evidence to confirm the presence or absence of breast cancer. The BCtect® gene expression signature consists of a unique set of 96 genes, including quality control genes. BCtect® is the first blood test to be offered as an adjunctive test to mammography to aid in the detection of early breast cancer..

History
BCtect® is the first blood test to be offered as an adjunctive test to mammography to aid in the detection of early breast cancer. In 1997, Anders Lönneborg and Praveen Sharma, patented the ide that

Drug interactions
== External links

–

[[Category:]]